5:10 AM
 | 
Sep 21, 2017
 |  BC Extra  |  Company News

Provention details pipeline

Provention Bio Inc. (Lebanon, N.J.), a newco pursuing autoimmune and inflammatory disease therapies, disclosed details on Thursday regarding two in-licensed programs from the Janssen unit of Johnson & Johnson (NYSE:JNJ).

Provention holds exclusive, worldwide rights to PRV-6527 (JNJ-40346527), an oral colony-stimulating factor 1...

Read the full 208 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >